16/12/2021 · Primary Outcome: • Negative RTPCR result on Day 6: 24% in IVM arm vs. 32% in placebo arm (rate ratio ; P = ) Secondary Outcomes: • Symptom resolution by Day 6: 84% in IVM arm vs. 90% in placebo arm (rate ratio ; P = ) Key Limitations: • The primary endpoint of the study was a negative SARSCoV2 RTPCR result on Day 6.